Primjena nanoterapeutika u liječenju tumora

Professional paper - Professional paper

• Author: Vesna Valentić
• Author: Mario Jug
• Author's institution: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of pharmaceutical technology)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Pharmacy

Abstract (english)

Nanopharmaceuticals ( 1 -100 nm) represent an opportunity of improving the
cancer treatment. Due to its unique characteristics, nanopharmaceuticals have many
advantages over conventional chemotherapy. The most important advantage is the
potential of targeted delivery of drugs to the tumor tissue resulting in lower systemic
toxicity which is the most prominent disadvantage of conventional chemocherapy.
Nanoparticles can passively reach the tumor tissue through the leaky vasculature
surrounding the tumor due to the increased permeability and retention effect. ln
active targeting, targeting ligands are attached at the surface of the nanocarrier for
binding to appropriate receptors overexpressed by the tumor cells or tumor vasculature
and not expressed by the normal cells. Stimuli-sensitive nanocarriers respond to
physical, chemical, or biological stimuli chat promote the release of the drug. Multifunctional
nanocarriers have several useful properties. Theranoscics are an emerging
subset of multifunctional nanocarriers which provide both the diagnosis and treatment
with the same nanoformulation. Various types of nanopharmaceuticals have
been used in clinical cancer treatment, including drug conjugates, lipid or polymerbased
nanocarriers and inorganic nanoparticles. At the present, the most successful
nanomedicine therapeutics in clinical cancer care are drug conjugates. Most clinically
available nanocarrier-based cancer therapeutics are passively targeted first-generation
nanomedicine drugs. In order to reach the target site, nanoparticles have to avoid
degradation by the mononuclear phagocyte system and renal filtration, extravasate
into tumor compartment, travel through the tumor stroma against high interstitial
fluid pressure gradients, and then interact with target cells or release the drug payload
for pharmacological effect. Therefore, for optimal delivery it is necessary to optimize
not only the physicochemical properties of the nanoparticles, but also to consider the
tumor microenvironment.

• Keywords (croatian): nanofarmaceutici; tumori; nanoterapeutici
• Language: croatian
• Publication type: Professional paper - Professional paper
• Publication status: Published
• Peer review: Peer review - domestic
• Publication version: Published version
• Journal title: Farmaceutski glasnik
• Numbering: vol. 71, no. 11, pp. 599-613
• p-ISSN: 0014-8202
• URN:NBN: urn:nbn:hr:163:298083
• Publication: 2015
• Type of resource: Text
• Access conditions: Open access
• Created on: 2021-02-17 12:34:31